Pericytes: Biomarkers and Roles in Thoracic Aortic Aneurysm
Stougiannou TM., Karangelis D.
Narrative Review, published in Genes (Basel) (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Genes (Basel) (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 42195012
- PMCID
- PMC13205215
- DOI
- 10.3390/genes17050555
Abstract (original English)
The aorta is the largest vascular conduit in humans, comprising three layers and a multitude of varying cell types collectively maintaining homeostasis and normal aortic wall function. Amongst these layers, the tunica adventitia is the external-most layer, where microvessels, termed vasa vasorum, can be found. These comprise pericytes and endothelial cells (ECs) and provide nourishment to the tunica adventitia and the outer media layers in the thoracic aorta. Adjacent to these microvessels, stem/progenitor group populations can be found, together forming a perivascular niche. Eventually, however, many of these cells and components can become dysregulated and contribute to development of thoracic aortic aneurysm (TAA). The purpose of this narrative review is to evaluate the recent literature related to marker gene expression in tunica adventitia pericytes, as well as the contribution of these populations to the development of aneurysm in the thoracic aorta. Pericytes in TAA generally exhibit phenotypic changes, which could be driven, in part, by loss of fibroblast growth factor (FGF) signaling. These changes eventually lead to vasa vasorum remodeling in the thoracic aorta, in turn contributing to the development of TAA.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.